Search results
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
Pharmaceutical Technology· 2 days agoBristol Myers Squibb has announced that the European Medicines Agency (EMA) will begin a review of...
AbbVie’s Humira loss of exclusivity has been a missed opportunity for competitors
Pharmaceutical Technology· 4 days agoThroughout AbbVie’s retooling efforts, its stiffest challenges have been with the evolving IL-23...
CatalYm secures $150m to advance GDF-15-targeting immune modulator
Pharmaceutical Technology· 4 days agoThe drug has so far been studied in combination with Bristol Myers Squibb's (BMS) anti-PD-1 drug...
Revolution sets sights on Phase III trial for pan-RAS inhibitor
Pharmaceutical Technology· 5 days agoIt is the most frequently mutated oncogene, meaning KRAS has been a target investigated by cancer...
Cardurion raises another $260M to fuel heart drug pipeline
BioPharma Dive· 5 days agoThe financing, which ranks as one of the year’s larger private rounds, will help the startup advance...
Vertex taps Orum to hunt for better ‘preconditioning’ drugs
BioPharma Dive· 5 days agoThe deal gives Vertex rights to use Orum’s ADC-like technology to discover gentler preparatory...
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
BioPharma Dive· 6 days agoUpdated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study...
Exploring Melbourne’s booming life sciences sector
Pharmaceutical Technology· 6 days agoHome to leading medical research institutes and one of the world’s largest biotechnology hubs, Australia is becoming the place to be for innovative life...
Lexeo gene therapy shows signs of heart benefit in small study
BioPharma Dive· 6 days agoThe biotech, which went public late last year, argued the results justify exploring an accelerated...